Paper Details

  1. Home
  2. Paper Details

Climodien (estradiol valerate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of postmenopausal complaints.

Author: GräserT, JanaudA, RömerT, WiedeyK D

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Climodien (estradiol valerate 2 mg plus dienogest 2 mg) was effective, safe, and well-tolerated for continuous combined hormone replacement therapy in postmenopausal women.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To evaluate the efficacy, safety and tolerability of continuous combined hormone replacement therapy (HRT) with Climodien (estradiol valerate 2 mg plus dienogest 2 mg). DESIGN: Open, multinational, multicenter, non-controlled phase III study. PARTICIPANTS: A total of 1501 women aged 52-...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/11770190

データ提供：米国国立医学図書館（NLM）

Climodien: A Safe and Effective Option for Postmenopausal Women

This research delves into the realm of women's health, evaluating the efficacy and safety of Climodien, a combined hormone replacement therapy (HRT) for managing postmenopausal symptoms. The study involved a large cohort of postmenopausal women experiencing various climacteric symptoms, including hot flushes and psychonervous disorders. The researchers meticulously tracked the women's responses to Climodien over a 12-week period, assessing both the effectiveness in alleviating symptoms and the safety profile of the treatment.

Climodien Demonstrates Efficacy and Safety in Postmenopausal Symptom Management

The results demonstrate that Climodien significantly improved Kupperman index scores, indicating a reduction in the severity of climacteric symptoms. Furthermore, the treatment was well-tolerated, with a favorable safety profile. The study highlights the potential of Climodien as a safe and effective option for managing postmenopausal symptoms, particularly for women who have not previously used HRT.

Finding Comfort in the Shifting Sands of Menopause

Menopause can be like traversing a desert, with fluctuating temperatures and shifting landscapes. This study offers a beacon of hope, showcasing Climodien as a safe and effective oasis for women navigating the challenges of menopause. It provides a valuable tool for addressing the physical and emotional discomfort associated with this life stage, offering a path towards greater comfort and well-being.

Dr.Camel's Conclusion

This research provides valuable insight into the efficacy and safety of Climodien for managing postmenopausal symptoms. Just as a desert traveler seeks respite from the harsh conditions, women experiencing menopause can find solace in the benefits of Climodien. The study underscores the importance of personalized care and evidence-based approaches in women's health, offering a path towards greater well-being for those navigating the unique challenges of this life stage.

Date :
  1. Date Completed 2002-05-22
  2. Date Revised 2018-11-30
Further Info :

Pubmed ID

11770190

DOI: Digital Object Identifier

11770190

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.